Table 3 Subgroup analysis by age and sex for association between SARS-CoV-2 vaccination or infection and outcome events using self-controlled case series analysis, adjusted for calendar month between 1 February 2021 and 28 February 2022.

From: Thrombocytopenia and venous thromboembolic events after BNT162b2, CoronaVac, ChAdOx1 vaccines and SARS-CoV-2 infection: a self-controlled case series study

 

BNT162b2

CoronaVac

ChAdOx1

SARS-CoV-2

Event

IRR (95% CI)

Event

IRR (95% CI)

Event

IRR (95% CI)

Event

IRR (95% CI)

Thrombocytopenia

 18–39 years

  Control period

529

1.00

201

1.00

36

1.00

138

1.00

  1st dose/infection, day 1–21

23

0.57 (0.37 to 0.89)

13

0.82 (0.43 to 1.56)

3

2.68 (0.65 to 11.07)

85

12.37 (9.18 to 16.66)

  2nd dose, day 1–21

33

0.84 (0.57 to 1.21)

8

0.55 (0.25 to 1.19)

< 3

**

–

–

 ≥ 40 years

  Control period

1156

1.00

666

1.00

75

1.00

297

1.00

  1st dose/infection, day 1–21

73

0.91 (0.71 to 1.17)

35

0.76 (0.52 to 1.11)

7

1.47 (0.62 to 3.51)

282

19.19 (15.99 to 23.04)

  2nd dose, day 1–21

79

1.00 (0.79 to 1.27)

49

1.05 (0.76 to 1.46)

8

1.69 (0.74 to 3.83)

–

–

 Male

  Control period

916

1.00

460

1.00

63

1.00

254

1.00

  1st dose/infection, day 1–21

51

0.82 (0.61 to 1.10)

27

0.85 (0.56 to 1.31)

6

1.29 (0.51 to 3.22)

222

16.79 (13.78 to 20.45)

  2nd dose, day 1–21

66

1.06 (0.82 to 1.38)

40

1.20 (0.84 to 1.72)

5

1.36 (0.50 to 3.73)

–

 

 Female

  Control period

878

1.00

407

1.00

48

1.00

242

1.00

  1st dose/infection, day 1–21

52

0.84 (0.63 to 1.12)

21

0.70 (0.43 to 1.13)

4

1.51 (0.48 to 4.71)

159

14.19 (11.32 to 17.78)

  2nd dose, day 1–21

51

0.84 (0.63 to 1.13)

17

0.58 (0.35 to 0.99)

4

1.56 (0.49 to 5.02)

–

–

Venous thromboembolism

 18–39 years

  Control period

563

1.00

227

1.00

27

1.00

227

1.00

  1st dose/infection, day 1–21

39

0.87 (0.62 to 1.23)

18

0.76 (0.45 to 1.30)

3

1.01 (0.24 to 4.16)

445

29.05 (24.12 to 35.00)

  2nd dose, day 1–21

28

0.67 (0.45 to 0.99)

18

0.70 (0.41 to 1.19)

2

0.51 (0.11 to 2.39)

–

–

 ≥ 40 years

  Control period

1585

1.00

845

1.00

118

1.00

723

1.00

  1st dose/infection, day 1–21

113

0.92 (0.76 to 1.12)

82

1.04 (0.80 to 1.34)

14

1.62 (0.86 to 3.04)

1477

30.31 (27.57 to 33.32)

  2nd dose, day 1–21

96

0.82 (0.67 to 1.02)

67

0.79 (0.61 to 1.03)

7

0.61 (0.28 to 1.35)

–

–

 Male

  Control period

993

1.00

528

1.00

88

1.00

466

1.00

  1st dose/infection, day 1–21

77

1.01 (0.80 to 1.29)

56

1.05 (0.78 to 1.43)

10

1.23 (0.60 to 2.52)

1032

32.42 (28.84 to 36.45)

  2nd dose, day 1–21

67

0.94 (0.73 to 1.21)

46

0.85 (0.62 to 1.18)

6

0.60 (0.25 to 1.42)

–

–

 Female

  Control period

1184

1.00

544

1.00

56

1.00

498

1.00

  1st dose/infection, day 1–21

76

0.86 (0.68 to 1.09)

44

0.94 (0.67 to 1.33)

7

2.53 (0.97 to 6.60)

897

27.40 (24.30 to 30.90)

  2nd dose, day 1–21

59

0.69 (0.52 to 0.90)

39

0.72 (0.51 to 1.03)

3

0.60 (0.18 to 2.03)

–

–

  1. Control period include days from 1 February 2021 to 28 February 2022 outside of the risk period (1–21 days post exposure), pre-risk period (− 14 to − 1 day before exposure), and day of exposure (day 0).
  2. CI confidence interval, IRR incidence rate ratio.
  3. **Value not computed for event count less than 3.
Back to article page